Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder

Last updated: December 4, 2016
Sponsor: Ruijin Hospital
Overall Status: Trial Status Unknown

Phase

2/3

Condition

Obsessive-compulsive Disorder

Mood Disorders

Panic Disorders

Treatment

N/A

Clinical Study ID

NCT02590445
OCD pilot
  • Ages 18-65
  • All Genders

Study Summary

Refractory obsessive-compulsive disorder (OCD) is a disabling condition. Deep brain stimulation (DBS) of ventral capsule/ventral striatum(VC/VS) is potentially the most effective treatment for refractory OCD. However, the affecting area of traditional electrodes is limited and not specific to VC/VS. The investigators designed a novel electrode, 2 mental contacts(3mm contact-2mm space-3 mm contact) could be implanted in ventral striatum and the other upper 2 contacts(4mm space-3mm contact-4mm space-3mm contact)that can be implanted in ventral capsule simultaneously, which the investigators believe will be more effective due to better compatibly with anatomical features of target area. This trial is to evaluate the effectiveness and safety of this approach.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age between 18 and 65 years.

  2. A primary diagnosis of OCD, defined according to the criteria of the Diagnostic andStatistical Manual of Mental Disorders, fifth edition (DSM-V).

  3. Chronic: at least a 3-year history of OCD symptoms with psychosocial dysfunction

  4. Severity: a score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) of more than 25 or one subscale score of more than 15 ; a score for severity of illness on theClinical Global Impression (CGI) scale of more than 4.

  5. Disability: a score on the Global Assessment Functioning (GAF) scale of less than 45or a score on Sheehan Disability Scale more than 24.

  6. Refractory: a lack of response to drug therapy after adequate administration, definedas more than two types of serotonin reuptake inhibitors at the maximum tolerated dosefor more than 12 weeks. Adequate behavior therapy, defined as more than 20 sessionspsychotherapy with experienced therapist.

  7. OCD medication regimen is stable for at least 4 weeks before enrollment.

Exclusion

Exclusion Criteria:

  1. Schizophrenic disorder; bipolar disorder; substance abuse or dependence (except fordependence on nicotine), as assessed with the use of the Mini-InternationalNeuropsychiatric Interview (MINI 6.0.0).

  2. Cluster A or B personality disorder according to DSM-IV-TR criteria, as assessed withthe use of the Structured Clinical Interview II.

  3. A current severe major depressive episode, determined according to DSM-V criteria (asassessed with the use of the MINI 6.0.0) and defined by the Hamilton Depression RatingScale-17 (HAMD) score of more than 20 and a risk of suicide.

  4. Abnormal cognitive status (measured by MoCA), abnormal findings on functional magneticresonance imaging (MRI) of the brain, or contraindications to surgery or anesthesia.

Study Design

Total Participants: 8
Study Start date:
October 01, 2015
Estimated Completion Date:
April 30, 2018

Connect with a study center

  • Shanghai Ruijin Hospital

    Shanghai, Shanghai 200025
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.